Cardinal Health enters CVS deal extension to 2032 and Cardinal Health stock costs EUR 212.45

Published on 10/12/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS distribution terms are planned through June 30, 2032, under the October 1 letter. Cardinal Health stock costs EUR 212.45 on October 12, 2026.

Key points in brief

Cardinal Health entered a binding letter of intent to extend its CVS Health distribution agreements through June 30, 2032.
Fiscal 2026 fourth-quarter revenue rose 6.00 percent to USD 63.70 billion, while GAAP diluted EPS rose 70.00 percent to USD 1.70.
Cardinal Health stock was at EUR 212.45 at Lang & Schwarz on October 12, 2026 at 11:49 a.m. CEST.
The company plans to release fiscal 2027 first-quarter results on November 5, 2026.

Farbenfroher Pop-Art-Comic mit Fahrer und Pflegerin beim Übergeben von Medizinpaketen — Pop-Art-Comic zeigt die Lieferung medizinischer Güter durch Cardinal Health Inc. ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health (ISIN US14149Y1082) entered a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 30, 2032, on October 1, 2026. Cardinal Health stock was at EUR 212.45 at Lang & Schwarz on October 12, 2026 at 11:49 a.m. CEST. The agreement gives the latest company event a defined duration while the market awaits the next results release.

CVS terms reach June 30, 2032

According to Cardinal Health on October 1, 2026, the company entered the binding letter of intent to extend its existing distribution agreement with CVS Health through June 30, 2032. The announcement links Cardinal Health to a long-dated pharmaceutical distribution relationship rather than a short contract renewal.

The company also plans to report fiscal 2027 first-quarter results on November 5, 2026, before trading opens in New York, according to Cardinal Health. That date is the next operational test for the distribution and medical products businesses.

What does the extension change?

The most recent reported quarter showed revenue of USD 63.70 billion, up 6.00 percent year over year, while GAAP diluted earnings per share increased 70.00 percent to USD 1.70, according to Cardinal Health in its fiscal 2026 fourth-quarter release dated August 11, 2026. The comparison matters because the CVS extension arrives alongside higher recent revenue and earnings, not as a standalone contract detail.

MarketBeat reported on October 9, 2026, that nineteen analysts carried a consensus Moderate Buy view, with sixteen Buy ratings and three Holds. The average twelve-month price target was USD 266.56, while fiscal 2027 earnings guidance was USD 12.40-12.60 per share, according to MarketBeat. The guidance range places the next earnings release at the center of the stock narrative.

Three company milestones

On April 30, 2026, Cardinal Health reported fiscal third-quarter revenue of USD 60.90 billion, up 11.00 percent year over year, according to Cardinal Health. On August 11, 2026, fiscal fourth-quarter revenue reached USD 63.70 billion and GAAP diluted EPS reached USD 1.70. On October 1, 2026, the CVS Health distribution extension was planned through June 30, 2032.

Next dates for shareholders

Cardinal Health is scheduled to release fiscal 2027 first-quarter results on November 5, 2026, according to its October 1 announcement. The quarterly dividend of USD 0.5158 per share is scheduled for payment on October 15, 2026, with the record date on October 1, 2026, according to MarketBeat.

Cardinal Health stock at Lang & Schwarz

Cardinal Health stock was at EUR 212.45 at Lang & Schwarz on October 12, 2026 at 11:49 a.m. CEST. The stock's primary listing is on the NYSE, where the October 9, 2026 close was USD 237.57, while the 52-week range was USD 151.87 to USD 258.30.

The further course of trading is shown by the continuously updated real-time quote of Cardinal Health stock.